Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
03
03
2021
accepted:
09
03
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
28
5
2021
Statut:
epublish
Résumé
It remains unknown whether and to what extent members of online "long COVID" peer support groups remain symptomatic and limited over time. Therefore, we aimed to evaluate symptoms in members of online long COVID peer support groups up to 6 months after the onset of coronavirus disease 2019 (COVID-19)-related symptoms. Demographics, symptoms, health status, work productivity, functional status and health-related quality of life were assessed about 3 and 6 months after the onset of COVID-19-related symptoms in members of online long COVID peer support groups. Data from 239 patients with a confirmed COVID-19 diagnosis (83% women; median (interquartile range) age 50 (39-56) years) were analysed. During the infection, a median (interquartile range) of 15 (11-18) symptoms was reported, which was significantly lower 3 and 6 months later: 6 (4-9) and 6 (3-8), respectively (p<0.05). From 3 to 6 months follow-up, the proportion of patients without symptoms increased from 1.3% to only 5.4% (p<0.001). Patients also reported a significantly improved work productivity (work absenteeism and presenteeism: 73% Although patients with confirmed COVID-19, who were all members of online long COVID peer support groups, reported significant improvements in work productivity, functional status and quality of life between 3 and 6 months follow-up, these data clearly highlight the long-term impact of COVID-19, as approximately 6 months after the onset of COVID-19-related symptoms a large proportion still experienced persistent symptoms, a moderate-to-poor health, moderate-to-severe functional limitations, considerable loss in work productivity, and/or an impaired quality of life. Action is needed to improve the management and healthcare of these patients.
Sections du résumé
BACKGROUND
BACKGROUND
It remains unknown whether and to what extent members of online "long COVID" peer support groups remain symptomatic and limited over time. Therefore, we aimed to evaluate symptoms in members of online long COVID peer support groups up to 6 months after the onset of coronavirus disease 2019 (COVID-19)-related symptoms.
METHODS
METHODS
Demographics, symptoms, health status, work productivity, functional status and health-related quality of life were assessed about 3 and 6 months after the onset of COVID-19-related symptoms in members of online long COVID peer support groups.
RESULTS
RESULTS
Data from 239 patients with a confirmed COVID-19 diagnosis (83% women; median (interquartile range) age 50 (39-56) years) were analysed. During the infection, a median (interquartile range) of 15 (11-18) symptoms was reported, which was significantly lower 3 and 6 months later: 6 (4-9) and 6 (3-8), respectively (p<0.05). From 3 to 6 months follow-up, the proportion of patients without symptoms increased from 1.3% to only 5.4% (p<0.001). Patients also reported a significantly improved work productivity (work absenteeism and presenteeism: 73%
CONCLUSION
CONCLUSIONS
Although patients with confirmed COVID-19, who were all members of online long COVID peer support groups, reported significant improvements in work productivity, functional status and quality of life between 3 and 6 months follow-up, these data clearly highlight the long-term impact of COVID-19, as approximately 6 months after the onset of COVID-19-related symptoms a large proportion still experienced persistent symptoms, a moderate-to-poor health, moderate-to-severe functional limitations, considerable loss in work productivity, and/or an impaired quality of life. Action is needed to improve the management and healthcare of these patients.
Identifiants
pubmed: 34041295
doi: 10.1183/23120541.00141-2021
pii: 00141-2021
pmc: PMC8012818
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: A.W. Vaes has nothing to disclose. Conflict of interest: Y.M.J. Goërtz has nothing to disclose. Conflict of interest: M. Van Herck has nothing to disclose. Conflict of interest: F.V.C. Machado has nothing to disclose. Conflict of interest: R. Meys has nothing to disclose. Conflict of interest: J.M. Delbressine has nothing to disclose. Conflict of interest: S. Houben-Wilke has nothing to disclose. Conflict of interest: S. Gaffron has nothing to disclose. Conflict of interest: D. Maier reports Biomax provides data management and analysis services to CIRO. Conflict of interest: C. Burtin has nothing to disclose. Conflict of interest: R. Posthuma has nothing to disclose. Conflict of interest: N.P.H. van Loon has nothing to disclose. Conflict of interest: F.M.E. Franssen reports grants and personal fees from AstraZeneca, and personal fees from Boehringer Ingelheim, Chiesi, GSK and TEVA, outside the submitted work. Conflict of interest: B. Hajian has nothing to disclose. Conflict of interest: S.O. Simons reports personal fees from AstraZeneca and grants from GSK, outside the submitted work. Conflict of interest: J.F.M. Van Boven has nothing to disclose. Conflict of interest: F.A. Klok reports grants from Bayer, Bristol Meyer Squibb, Boehringer Ingelheim, MSD, Daiichi-Sankyo, Actelion, the Dutch Thrombosis Association, the Dutch Heart Foundation, and the Netherlands Organisation for Health Research and Development, outside the submitted work. Conflict of interest: B. Spaetgens has nothing to disclose. Conflict of interest: C.M.H. Pinxt has nothing to disclose. Conflict of interest: L.Y.L. Liu has nothing to disclose. Conflict of interest: G. Wesseling has nothing to disclose. Conflict of interest: Y. Spies has nothing to disclose. Conflict of interest: H. Vijlbrief has nothing to disclose. Conflict of interest: A.J. Van ’t Hul has nothing to disclose. Conflict of interest: D.J.A. Janssen reports personal fees from AstraZeneca, Boehringer Ingelheim and Novartis, outside the submitted work. Conflict of interest: M.A. Spruit reports grants from Lung Foundation Netherlands and Stichting Astma Bestrijding, and grants and personal fees from AstraZeneca and Boehringer Ingelheim, outside the submitted work.
Références
Clin Microbiol Infect. 2020 Nov;26(11):1448-1449
pubmed: 32712242
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
J Clin Med. 2020 Sep 12;9(9):
pubmed: 32932582
Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32398306
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Thorax. 2020 Dec 3;:
pubmed: 33273028
Clin Infect Dis. 2020 Nov 21;:
pubmed: 33220049
Thorax. 2020 Jan;75(1):17-27
pubmed: 31704795
Respir Res. 2019 Dec 21;20(1):291
pubmed: 31864411
Clin Infect Dis. 2020 Nov 30;:
pubmed: 33252665
Value Health. 2016 Jun;19(4):343-52
pubmed: 27325326
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
Health Qual Life Outcomes. 2021 Feb 3;19(1):40
pubmed: 33536042
N Engl J Med. 2020 Aug 6;383(6):e38
pubmed: 32502334
Crit Care Clin. 2011 Jul;27(3):685-704
pubmed: 21742223
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Eur J Health Econ. 2019 Aug;20(6):933-944
pubmed: 31030292
Eur Respir J. 2020 Nov 26;56(5):
pubmed: 33008936
Sci Rep. 2017 Dec 8;7(1):17275
pubmed: 29222500
Am J Respir Crit Care Med. 2005 Feb 15;171(4):340-7
pubmed: 15542793
ERJ Open Res. 2021 Feb 08;7(1):
pubmed: 33575312
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
BMC Health Serv Res. 2020 Dec 20;20(1):1144
pubmed: 33342437
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910